Skip to main content

HEALTH

  • East Coast reeling from flu, bug begins making its trek west

    ATLANTA — The worst of the flu season may be over, at least for those on the East Coast. In a late morning press conference with reporters on Friday, Thomas Frieden, director of the Centers for Disease Control and Prevention, said, "We are seeing a decrease in some regions." 

    Just don't tell that to anyone living in New York, Boston or Chicago, at least not before slipping on a facemask first.  

  • Study: Egg allergies may not be automatic disqualifier for getting flu shot

    ARLINGTON HEIGHTS, Ill. — Egg allergies may no longer be a valid reason to not get a flu shot, the American College of Allergy, Asthma and Immunology announced Friday. 

  • Konsyl Pharmaceuticals names VP sales, marketing

    EASTON, Md. — Konsyl Pharmaceuticals on Wednesday named Roger Giannico VP sales and marketing. Giannico has more than 25 years of experience in health care product sales and marketing management, most recently at ChaseHealthAdvance Patient Financing, a division of JP Morgan Chase. 

    Giannico earned his MBA at Dowling College in Oakdale, N.Y., and has been an adjunct professor at Stony Brook University.

  • Ferndale Healthcare launches new site

    FERNDALE, Mich. — Ferndale Healthcare on Thursday unveiled a redesigned corporate web site www.ferndalehealthcare.com to make it easier for a variety of target audiences to navigate the site.

  • Survey: Most moms concerned about breastfeeding in public

    WASHINGTON — Most U.S. moms are concerned about breastfeeding in public even though they understand that breastfeeding is the best way to feed their babies, according to the 2012 Lansinoh Breastfeeding Study released Thursday. 

    “Breastfeeding in public became one of the hottest publicly debated topics in 2012," stated Gina Ciagne, senior director, professional relations at Lansinoh. "We were interested to find out how that affected moms’ decisions to breastfeed.” 

  • FDA panel recommends approval for J&J Type 2 diabetes drug

    RARITAN, N.J. -- A panel of Food and Drug Administration experts has recommended approval for an experimental Type 2 diabetes drug made by Johnson & Johnson, the drug maker said.

    J&J said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had recommended approval for canagliflozin, which the company plans to market under the name brand Invokana. The FDA is not required to follow the votes of advisory committees when deciding whether or not to approve a drug, but usually does.

  • CDC: Influenza rates may have reached a peak, at least in the Southeast

    ATLANTA — The worst of the flu season may be over, at least for those in the South. In a late morning press conference with reporters, Thomas Frieden, director of the Centers for Disease Control and Prevention, said, "We are seeing a decrease in some regions."

  • Giant Eagle locks in prices for the winter on hundreds of items

    PITTSBURGH — Giant Eagle on Thursday announced a new Winter Low Price Lock on hundreds of popular products. 

X
This ad will auto-close in 10 seconds